Pre-made Zansecimab benchmark antibody ( Whole mAb, anti-ANGPT2 therapeutic antibody, Anti-AGPT2/ANG2/LMPHM10 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Zansecimab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Zansecimab (formerly LY 3127804) is a selective monoclonal antibody against angiopoietin 2 (Ang2), being developed by Eli Lilly and Company, for the treatment of solid tumours including gastric cancer and hepatocellular carcinoma (HCC) and COVID-19 pneumonia.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-641-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Zansecimab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody
INN Name	Zansecimab
Target	ANGPT2
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	na
Companies	Eli Lilly
Conditions Approved	na
Conditions Active	COVID-19
Conditions Discontinued	Solid tumours
Development Tech	na